Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Improving Turnaround Time in a Hospital-based CT Division with the Kaizen Method
Flug, Jonathan A. , Stellmaker, Jessica A. , Tollefson, Chris , Comstock, Elaine M. , Buelna, Efren, Truman, Brooke, Ponce, Lisa , Milosek, Amy , McCabe, J.F., Jokerst, Clinton, Tollefson, Chris D , McCabe, John, Jokerst, Clinton E , Flug, Jonathan A , McCabe, John

Mayo Clinic

RadioGraphics | May 27, 2022 | Volume: 42 | Issue: 4 | Pages: E125-E131

10.1148/rg.210128 | PMID 35622490 Get It

Drug Interactions Affecting Oral Anticoagulant Use
Mar, Philip L. , Gopinathannair, Rakesh , Gengler, Brooke , Chung, Mina K. , Perez, Arturo, Dukes, Jonathan W., Ezekowitz, Michael D. , Lakkireddy, Dhanunjaya , Miletello, Mike, Reiffel, James A. , Gengler, Brooke E , Lip, Gregory Y H , Miletello, Mike , Noseworthy, Peter A , Reiffel, James A , Tisdale, James E , Olshansky, Brian , Gopinathannair, Rakesh , Noseworthy, Peter A. , Olshansky, Brian

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 27, 2022 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/circep.121.007956 | PMID 35622425 Get It

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are an important cause of adverse drug reactions and exact a large toll on the health care system. DDI for warfarin mainly involve moderate to strong inhibitors/inducers of cytochrome P450 (CYP) 2C9, which is responsible for the elimination of the more potent S-isomer of warfarin. However, inhibitor/inducers of CYP3A4 and CYP1A2 may also cause DDI with warfarin. Recognition of these precipitating agents along with increased frequency of monitoring when these agents are initiated or discontinued will minimize the impact of warfarin DDI. Direct oral anticoagulants are mainly affected by medications strongly affecting the permeability glycoprotein (P-gp), and to a lesser extent, strong CYP3A4 inhibitors/inducers. Dabigatran and edoxaban are affected by P-gp modulation. Strong inducers of CYP3A4 or P-gp should be avoided in all patients taking direct oral anticoagulant unless previously proven to be otherwise safe. Simultaneous strong CYP3A4 and P-gp inhibitors should be avoided in patients taking apixaban and rivaroxaban. Concomitant antiplatelet/anticoagulant use confers additive risk for bleeding, but their combination is unavoidable in many cases. Minimizing duration of concomitant anticoagulant/antiplatelet therapy as indicated by evidence-based clinical guidelines is the best way to reduce the risk of bleeding.
Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease
Vöglein, Jonathan , Morris, John C. , Dieterich, Marianne , Preische, Oliver, Hofmann, Anna, Hassenstab, Jason , Fagan, Anne M. , Noble, James M. , Berman, Sarah , Graff‐Radford, Neill R. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Salloway, Stephen , Xiong, Chengjie , Cairns, Nigel J., Perrin, Richard J. , Day, Gregory S. , Mori, Hiroshi , Suzuki, Kazushi , Masters, Colin L. , Goate, Alison , Buckles, Virginia, Fox, Nick C. , Chrem, Patricio, Ringman, John M. , Yakushev, Igor , Laske, Christoph , Bateman, Randall J. , Network, for the Dominantly Inherited Alzheimer, Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Franzmeier, Nicolai , McDade, Eric , Simons, Mikael , Benzinger, Tammie L.S. , Ghetti, Bernardino , Xiong, Chengjie , Karch, Celeste M. , Martins, Ralph N. , Sánchez‐Valle, Raquel , Shimada, Hiroyuki , Ikeuchi, Takeshi , Schofield, Peter R. , Allegri, Ricardo , Jucker, Mathias , Höglinger, Günter U. , Danek, Adrian , Network, for the Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | May 24, 2022 | Volume: 19 | Issue: 2 | Pages: 632-645

10.1002/alz.12684 | PMID 35609137 Get It

AbstractIntroductionAs knowledge about neurological examination findings in autosomal dominant Alzheimer disease (ADAD) is incomplete, we aimed to determine the frequency and significance of neurological examination findings in ADAD.MethodsFrequencies of neurological examination findings were compared between symptomatic mutation carriers and non mutation carriers from the Dominantly Inherited Alzheimer Network (DIAN) to define AD neurological examination findings. AD neurological examination findings were analyzed regarding frequency, association with and predictive value regarding cognitive decline, and association with brain atrophy in symptomatic mutation carriers.ResultsAD neurological examination findings included abnormal deep tendon reflexes, gait disturbance, pathological cranial nerve examination findings, tremor, abnormal finger to nose and heel to shin testing, and compromised motor strength. The frequency of AD neurological examination findings was 65.1%. Cross‐sectionally, mutation carriers with AD neurological examination findings showed a more than two‐fold faster cognitive decline and had greater parieto‐temporal atrophy, including hippocampal atrophy. Longitudinally, AD neurological examination findings predicted a significantly greater decline over time.DiscussionADAD features a distinct pattern of neurological examination findings that is useful to estimate prognosis and may inform clinical care and therapeutic trial designs.
Infrapedicular approach to CT-guided thermal ablation in the thoracic spine
Burkett, Brian J. , Kim, Dong Kun , Benson, John C. , Burkett, Brian , Benson, John , Carr, Carrie, Carr, Carrie M. , Morris, Jonathan M.

Mayo Clinic

The Neuroradiology Journal | May 18, 2022 | Volume: 35 | Issue: 6 | Pages: 736-741

10.1177/19714009221096827 | PMID 35574645 Get It

Objectives The aim of this study is to introduce the infrapedicular approach to CT-guided spine interventions, a specialized technique that can safely expand the scope of spine lesions amenable to treatment, and to document the feasibility in a variety of procedural scenarios to the extent possible with a retrospective case series. Methods Data from 24 cases performed at a single institution over a 10-year period were retrospectively reviewed to assess the technical feasibility and safety profile of the technique. Results The infrapedicular approach enabled a technically satisfactory procedural result in 24 cases (mean age 63.9 years, range 35–83 years). Two peri-procedural complications occurred, including a small pneumothorax and a cerebrospinal fluid leak, both of which resolved with conservative treatment. No lasting injurious effects or additional complications were identified. The infrapedicular approach was found to be particularly useful in multiple technically challenging scenarios: it facilitates access to lesions in the inferior vertebral body, allows biopsy, cement augmentation, or ablation of high thoracic lesions difficult to treat due to limitations of steep angulation of fluoroscopy and CT scanners, and enables treatment of large lesions by using multiple overlapping probes.
Utility of Biomarkers for Sepsis-Associated Acute Kidney Injury Staging
Molinari, Luca , Smith, A.J. Conrad , Landsittel, Douglas , Singbartl, Kai , Yealy, Donald M., Kellum, John A. , Investigators, ProCESS and ProGReSS-AKI, Keener, Christopher, Lucko, Nicole, Pike, Francis, Yende, Sachin , Gimbel, Elizabeth, Landis, Kyle, Stapleton, Diana K., Weissfeld, Lisa A., Willochell, Michael, Wofford, Kourtney A., Watts, Hannah , Venkat, Arvind , Hou, Peter C. , Massaro, Anthony F., Parmar, Siddharth , Brewer, Kori L. , Delbridge, Theodore R. , Mainhart, Allison, Miner, James R. , Allen, Todd L., Grissom, Colin K. , Swadron, Stuart P., Carlson, Richard, LoVecchio, Frank , Parry, Blair A. , Ellender, Timothy J., Sama, Andrew E., Fine, Jonathan , Nafeei, Soheil, Wojnar, Margaret, Pearl, Ronald G. , Wilber, Scott T., Sinert, Richard , Orban, David J., Ufberg, Jacob W. , Albertson, Timothy, Panacek, Edward A., Parekh, Sohan, Gunn, Scott R. , Rittenberger, Jon S., Wadas, Richard J. , Edwards, Andrew R., Holmes, T., Weinert, Craig , Harris, Estelle S. , Self, Wesley H. , Dubinski, Diane, Phillips, Carolyn, Migues, Ronald M., Singbartl, Kai , Kellum, John A , Rio‐Pertuz, Gaspar Del , Palevsky, Paul M. , Chawla, Lakhmir S. , Huang, David T. , Angus, Derek C. , Investigators, ProCESS and ProGReSS-AKI, Barnato, Amber E. , Eaton, Tammy L. , Kulstad, Erik Benjamin , Limkakeng, Alexander T. , Conrad, Steven A. , Bajwa, Ednan K. , Filbin, Michael R. , Terndrup, Thomas E. , Wilson, Jason W. , Kelly, Matthew, Wang, Henry E. , McCurdy, Michael T. , Phillips, Carolyn A

Mayo Clinic

JAMA Network Open | May 18, 2022 | Volume: 5 | Issue: 5 | Pages: e2212709

10.1001/jamanetworkopen.2022.12709 | PMID 35583867 Get It

Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology
Schofield, Peter R. , Weiner, Michael W. , Xiong, Chengjie , Coble, Dean W. , Saito, Naomi , Aisen, Paul, Berman, Sarah , Cairns, Nigel J., Carrillo, María C. , Chui, Helena C., Chhatwal, Jasmeer P. , Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Graff‐Radford, Neill R. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jagust, William J. , Massoumzadeh, Parinaz , Masters, Colin L. , Mori, Hiroshi , Noble, James M. , Petersen, Ronald C. , Ringman, John M. , Salloway, Stephen , Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Vöglein, Jonathan , Weninger, Stacie, Bateman, Randall J. , Buckles, Virginia, Morris, John C. , Schofield, Peter R , Gordon, Brian A , Ikeuchi, T , Jack, Clifford R , Jagust, William J , Masters, Colin L , Vöglein, Jonathan , Saykin, Andrew J , Day, Gregory S , Bateman, Randall J , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Noble, James M , Xiong, Chengjie , Beckett, Laurel , Allegri, Ricardo , Benzinger, Tammie L.S. , Chui, Helena C. , Cruchaga, Carlos , Ghetti, Bernardino , Ikeuchi, Takeshi , Jucker, Mathias , Martins, Ralph N. , McDade, Eric , Toga, Arthur W.

Mayo Clinic

Brain | May 17, 2022 | Volume: 145 | Issue: 10 | Pages: 3594-3607

10.1093/brain/awac181 | PMID 35580594 Get It

AbstractThe extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the pathophysiology of ‘sporadic’ late onset Alzheimer's disease is unknown, thus limiting the extrapolation of study findings and clinical trial results in autosomal dominant Alzheimer's disease to late onset Alzheimer's disease.We compared brain MRI and amyloid PET data, as well as CSF concentrations of amyloid-β42, amyloid-β40, tau and tau phosphorylated at position 181, in 292 carriers of pathogenic variants for Alzheimer's disease from the Dominantly Inherited Alzheimer Network, with corresponding data from 559 participants from the Alzheimer’s Disease Neuroimaging Initiative. Imaging data and CSF samples were reprocessed as appropriate to guarantee uniform pipelines and assays. Data analyses yielded rates of change before and after symptomatic onset of Alzheimer's disease, allowing the alignment of the ∼30-year age difference between the cohorts on a clinically meaningful anchor point, namely the participant age at symptomatic onset.Biomarker profiles were similar for both autosomal dominant Alzheimer's disease and late onset Alzheimer's disease. Both groups demonstrated accelerated rates of decline in cognitive performance and in regional brain volume loss after symptomatic onset. Although amyloid burden accumulation as determined by PET was greater after symptomatic onset in autosomal dominant Alzheimer's disease than in late onset Alzheimer's disease participants, CSF assays of amyloid-β42, amyloid-β40, tau and p-tau181 were largely overlapping in both groups. Rates of change in cognitive performance and hippocampal volume loss after symptomatic onset were more aggressive for autosomal dominant Alzheimer's disease participants.These findings suggest a similar pathophysiology of autosomal dominant Alzheimer's disease and late onset Alzheimer's disease, supporting a shared pathobiological construct.
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Pacheco, Jose M., Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 497-530

10.6004/jnccn.2022.0025 | PMID 35545176 Get It

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
PET Imaging of Dementia
Burkett, Brian J. , Babcock, Jeffrey C., Lowe, Val J. , Graff‐Radford, Jonathan , Subramaniam, Rathan M. , Burkett, Brian , Babcock, Jeffrey , Johnson, Derek R.

Mayo Clinic

Clinical Nuclear Medicine | May 11, 2022 | Volume: 47 | Issue: 9 | Pages: 763-773

10.1097/rlu.0000000000004251 | PMID 35543643 Get It

Abstract PET imaging plays an essential role in achieving earlier and more specific diagnoses of dementia syndromes, important for clinical prognostication and optimal medical management. This has become especially vital with the recent development of pathology-specific disease-modifying therapy for Alzheimer disease, which will continue to evolve and require methods to select appropriate treatment candidates. Techniques that began as research tools such as amyloid and tau PET have now entered clinical use, making nuclear medicine physicians and radiologists essential members of the care team. This review discusses recent changes in the understanding of dementia and examines the roles of nuclear medicine imaging in clinical practice. Within this framework, multiple cases will be shown to illustrate a systematic approach of FDG PET interpretation and integration of PET imaging of specific molecular pathology including dopamine transporters, amyloid, and tau. The approach presented here incorporates contemporary understanding of both common and uncommon dementia syndromes, intended as an updated practical guide to assist with the sophisticated interpretation of nuclear medicine examinations in the context of this rapidly and continually developing area of imaging.
Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation
Sandoval, Yader , Lewis, Bradley R., Mehta, Ramila A. , Ola, Olatunde , Knott, Jonathan D , Michieli, Laura De , Akula, Ashok , Lobo, Ronstan , Gharacholou, S. Michael , Dworak, Marshall , Crockford, Erika, Rastas, Nicholas, Grube, Eric , Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Lewis, Bradley R , De Michieli, Laura , Dworak, Marshall , Gulati, Rajiv , Jaffe, Allan S. , Yang, Eric H. , Grube, Eric

Mayo Clinic

Circulation | May 10, 2022 | Volume: 145 | Issue: 23 | Pages: 1708-1719

10.1161/circulationaha.122.059235 | PMID 35535607 Get It

Background: There are good data to support using a single high-sensitivity cardiac troponin T (hs-cTnT) below the limit of detection of 5 ng/L to exclude acute myocardial infarction. Per the US Food and Drug Administration, hs-cTnT can only report to the limit of quantitation of 6 ng/L, a threshold for which there are limited data. Our goal was to determine whether a single hs-cTnT below the limit of quantitation of 6 ng/L is a safe strategy to identify patients at low risk for acute myocardial injury and infarction. Methods: The efficacy (proportion identified as low risk based on baseline hs-cTnT<6 ng/L) of identifying low-risk patients was examined in a multicenter (n=22 sites) US cohort study of emergency department patients undergoing at least 1 hs-cTnT (CV Data Mart Biomarker cohort). We then determined the performance of a single hs-cTnT<6 ng/L (biomarker alone) to exclude acute myocardial injury (subsequent hs-cTnT >99th percentile in those with an initial hs-cTnT<6 ng/L). The clinically intended rule-out strategy combining a nonischemic ECG with a baseline hs-cTnT<6 ng/L was subsequently tested in an adjudicated cohort in which the diagnostic performance for ruling out acute myocardial infarction and safety (myocardial infarction or death at 30 days) were evaluated. Results: A total of 85 610 patients were evaluated in the CV Data Mart Biomarker cohort, among which 24 646 (29%) had a baseline hs-cTnT<6 ng/L. Women were more likely than men to have hs-cTnT<6 ng/L (38% versus 20%, P <0.0001). Among 11 962 patients with baseline hs-cTnT<6 ng/L and serial measurements, only 1.2% developed acute myocardial injury, resulting in a negative predictive value of 98.8% (95% CI, 98.6–99.0) and sensitivity of 99.6% (95% CI, 99.5–99.6). In the adjudicated cohort, a nonischemic ECG with hs-cTnT<6 ng/L identified 33% of patients (610/1849) as low risk and resulted in a negative predictive value and sensitivity of 100% and a 30-day rate of 0.2% for myocardial infarction or death. Conclusions: A single hs-cTnT below the limit of quantitation of 6 ng/L is a safe and rapid method to identify a substantial number of patients at very low risk for acute myocardial injury and infarction.
Racial Disparities in the Use of Peripheral Nerve Blocks for Postoperative Analgesia After Total Mastectomy: A Retrospective Cohort Study
Mazzeffi, Michael , Teal, Christine, Douglas, Rundell, Starks, Vanessa, Chow, Jonathan H. , Keneally, Ryan J. , Porter, Steven B.

Mayo Clinic

Anesthesia & Analgesia | May 6, 2022 | Volume: 135 | Issue: 1 | Pages: 170-177

10.1213/ane.0000000000006058 | PMID 35522889 Get It

BACKGROUND: Peripheral nerve blocks (PNBs) are used to provide postoperative analgesia after total mastectomy. PNBs improve patient satisfaction and decrease postoperative opioid use, nausea, and vomiting. Few studies have examined whether there is racial-ethnic disparity in the use of PNBs for patients having total mastectomy. We hypothesized that non-Hispanic Asian, non-Hispanic Black, non-Hispanic patients of other races, and Hispanic patients would be less likely to receive a PNB for postoperative analgesia compared to non-Hispanic White patients having total mastectomy. Secondarily, we hypothesized that PNBs would be associated with reduced odds of major complications after total mastectomy. METHODS: We performed a retrospective cohort study using National Surgical Quality Improvement Program (NSQIP) data from 2015 to 2019. Patients were included if they underwent total mastectomy under general anesthesia. Unadjusted rates of PNB use were compared between race-ethnicity groups. Multivariable logistic regression was performed to determine whether race-ethnicity group was independently associated with receipt of a PNB for postoperative analgesia. Secondarily, we calculated crude and risk-adjusted odds ratios for major complications in patients who received a PNB. RESULTS: There were 64,103 patients who underwent total mastectomy and 4704 (7.3%) received a PNB for postoperative analgesia. Patients who received a PNB were younger, more commonly women, were less likely to have diabetes and hypertension, and had less disseminated cancer (all P < .05). In our regression analysis, the odds of receiving a PNB differed significantly by race-ethnicity group ( P < .001). Non-Hispanic Asian and non-Hispanic Black patients had reduced odds of receiving a PNB compared to non-Hispanic White patients (odds ratio [OR], 0.41; 95% confidence interval [CI], 0.33–0.49 and OR, 0.37 [0.32–0.44]), respectively. Non-Hispanic patients of other races, including American Indian, Alaskan Native, and Pacific Islander, also had reduced odds of receiving a PNB (OR, 0.73 [95% CI, 0.64–0.84]) compared to non-Hispanic White patients, as did Hispanic patients (OR, 0.62 [0.56–0.69]). Patients who received a PNB did not have reduced odds of major complications after mastectomy (crude OR, 0.83 [0.65–1.08]; P = .17 and adjusted OR, 0.85 [0.65–1.10]; P = .21). CONCLUSIONS: Significant disparity exists in the use of PNBs for postoperative analgesia in patients of different race-ethnicity who undergo total mastectomy in the United States. Continued efforts are needed to better understand the causes of disparity and to ensure equitable access to PNBs.